Prevention of hepatitis C in Japan: a lesson for us all

Lancet

Volumn 370, Issue 9604, 2007, Pages 1982-1983

  Heneghan, Carl ^a   Perera, Rafael ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIARRHYTHMIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN; THALIDOMIDE; TROGLITAZONE;

ARTICLE; DISEASE TRANSMISSION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; NONHUMAN; PRIORITY JOURNAL;

EID: 37149038588     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61842-X     Document Type: Note

References (15)

1. Yasunaga H. Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan. Lancet 370 (2007) 2063-2067
2. World Health Organization. Fact sheet number 164. Revised October, 2000. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed May 10, 2007).
3. Perz J., Armstrong G., Farrington L., Hutin Y., and Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
4. NIH consensus conference statement. Management of hepatitis C (June 10-12, 2007). http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm (accessed May 11, 2007).
5. Abocar A. Criminal charges laid in Canadian blood scandal. Reuters (Toronto) (Nov 21, 2002). http://www.aegis.com/news/re/2002/RE021126.html (accessed May 11, 2007).
6. The Daily Record (Scotland) (Oct 31, 2005). http://www.dailyrecord.co.uk/news/tm_objectid=16314330&method=full &siteid=66633&headline=clinton-s-scottish-court-warning--name_page .html (accessed May 11, 2007).
7. Hoofnagle J., Gerety R., Tabor E., Feinstone S., Barker L., and Purcell R. Transmission of non-A, non-B hepatitis. Ann Intern Med 87 (1977) 14-20
8. Aach R., Szmuness W., Mosley J., et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 304 (1981) 989-994
9. Franciscus A. HCV Advocate. Japanese state and firm blamed for hepatitis C infection. http://209.41.169.29/news/newsRev/2006/NewsRev-158.html#13 (accessed May 18, 2007).
10. Echt D., Liebson P., Mitchell L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
11. Vandenbroucke J. Thalidomide: an unanticipated adverse event. http://www.jameslindlibrary.org (accessed May 10, 2007).
12. Graham D., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
13. Evans I., Thornton H., and Chalmers I. New-but no better or even worse. In: Evans I., Thornton H., and Chalmers I. (Eds). Testing treatments: better research for better healthcare (2006), British Library Publishing Division, London 1-13
14. Doust J., and Del Mar C. Why do doctors use treatments that do not work?. BMJ 328 (2004) 474-475
15. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ 328 (2004) 475-476